Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation
GS Horan, S Wood, V Ona, DJ Li… - American journal of …, 2008 - atsjournals.org
GS Horan, S Wood, V Ona, DJ Li, ME Lukashev, PH Weinreb, KJ Simon, K Hahm, NE Allaire…
American journal of respiratory and critical care medicine, 2008•atsjournals.orgRationale: Transforming growth factor (TGF)-β has a central role in driving many of the
pathological processes that characterize pulmonary fibrosis. Inhibition of the integrin αvβ6, a
key activator of TGF-β in lung, is an attractive therapeutic strategy, as it may be possible to
inhibit TGF-β at sites of αvβ6 up-regulation without affecting other homeostatic roles of TGF-
β. Objectives: To analyze the expression of αvβ6 in human pulmonary fibrosis, and to
functionally test the efficacy of therapeutic inhibition of αvβ6-mediated TGF-β activation in …
pathological processes that characterize pulmonary fibrosis. Inhibition of the integrin αvβ6, a
key activator of TGF-β in lung, is an attractive therapeutic strategy, as it may be possible to
inhibit TGF-β at sites of αvβ6 up-regulation without affecting other homeostatic roles of TGF-
β. Objectives: To analyze the expression of αvβ6 in human pulmonary fibrosis, and to
functionally test the efficacy of therapeutic inhibition of αvβ6-mediated TGF-β activation in …
Rationale: Transforming growth factor (TGF)-β has a central role in driving many of the pathological processes that characterize pulmonary fibrosis. Inhibition of the integrin αvβ6, a key activator of TGF-β in lung, is an attractive therapeutic strategy, as it may be possible to inhibit TGF-β at sites of αvβ6 up-regulation without affecting other homeostatic roles of TGF-β.
Objectives: To analyze the expression of αvβ6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of αvβ6-mediated TGF-β activation in murine bleomycin–induced pulmonary fibrosis.
Methods: Lung biopsies from patients with a diagnosis of systemic sclerosis or idiopathic pulmonary fibrosis were stained for αvβ6 expression. A range of concentrations of a monoclonal antibody that blocks αvβ6-mediated TGF-β activation was evaluated in murine bleomycin–induced lung fibrosis.
Measurements and Main Results: αvβ6 is overexpressed in human lung fibrosis within pneumocytes lining the alveolar ducts and alveoli. In the bleomycin model, αvβ6 antibody was effective in blocking pulmonary fibrosis. At high doses, there was increased expression of markers of inflammation and macrophage activation, consistent with the effects of TGF-β inhibition in the lung. Low doses of antibody attenuated collagen expression without increasing alveolar inflammatory cell populations or macrophage activation markers.
Conclusions: Partial inhibition of TGF-β using αvβ6 integrin antibodies is effective in blocking murine pulmonary fibrosis without exacerbating inflammation. In addition, the elevated expression of αvβ6, an activator of the fibrogenic cytokine, TGF-β, in human pulmonary fibrosis suggests that αvβ6 monoclonal antibodies could represent a promising new therapeutic strategy for treating pulmonary fibrosis.
ATS Journals